Safety and Efficacy of Ritonavir (ABT-538) in Combination With Nelfinavir in HIV-Infected Subjects.

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baltimore,
Maryland21287

Purpose:

The purpose of this study is to see if it is safe and effective to give ritonavir plus
nelfinavir to HIV-infected patients. This study will also see how ritonavir and nelfinavir
are absorbed by the body and how they affect the level of HIV in the blood.

Criteria:

Inclusion Criteria
Patients must have:
- Documentation of a positive ELISA test for HIV confirmed by immunoblot, or a positive
HIV RNA test using the Roche PCR assay, or the Chiron bDNA assay.
- HIV RNA measurement of > 5,000 copies/ml within 3 weeks of baseline visit.
- Signed, informed consent from parent or legal guardian for patients less than 18
years of age.
- Access to a refrigerator for storing study drug.
Prior Medication:
Allowed:
Anti-HIV therapy other than protease inhibitor therapy.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- Evidence of acute infection, as measured by vital signs, physical examination,
12-lead electrocardiogram and laboratory assessments.
- Condition that may obscure the proper observation of the safety or activity of the
treatment regimens.
Concurrent Medication:
Excluded:
- Midazolam, alprazolam, clorazepate, diazepam, estazolam, flurazepam, triazolam,
zolpidem, quinidine, amiodarone, encainide, flecainide, propafenone, bepridil,
terfenadine, astemizole, cisapride, bupropion, clozapine, rifabutin, meperidine,
propoxyphene, piroxicam, pimozide, ergotamine, dihydroergotamine, and rifampin.
- Anti-retroviral therapy initiated prior to study entry.
- Any other medication, including over-the-counter medicine and alcohol, taken without
the permission of the primary investigator.
Patients with the following prior conditions are excluded:
- History of significant drug hypersensitivity.
- History of psychiatric illness that would preclude compliance with the protocol.
- Prior enrollment in this study.
Prior Medication:
Excluded:
- Investigational drugs within 30 days prior to drug administration.
- Prior treatment with licensed or investigational HIV protease inhibitor.
1. Active substance abuse.
- Positive urine screen for recreational drugs. NOTE:
- The presence of cannabis is not exclusionary unless the investigator believes its use
will interfere with patient compliance.

NCT ID:

NCT00002201

Primary Contact:

N/A

Backup Contact:

N/A

Location Contact:

Baltimore, Maryland 21287United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 21, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.